Millstone Evans Group’s AstraZeneca AZN Stock Holding History

Millstone Evans Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3K	Buy	+107	New	+$20.1K	0.01%	497
2026 Q1	–	Sell	-21	Closed	-$3.86K	–	859
2025 Q4	$3.86K	Hold	21	–	–	﹤0.01%	678
2025 Q3	$3.22K	Hold	21	–	–	﹤0.01%	688
2025 Q2	$2.94K	Sell	21 -31	-60%	-$4.34K	﹤0.01%	639
2025 Q1	$7.57K	Buy	52 +31	+148%	+$4.49K	0.01%	550
2024 Q4	$2.75K	Buy	+21	New	+$2.94K	﹤0.01%	624

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millstone Evans Group's AZN Position: Q2 2026 in Review

Millstone Evans Group opened a new position in AstraZeneca (AZN) in Q2 2026: 107 shares worth $20.3K. The stake represents 0.01% of the portfolio and ranks #497 among its holdings. This is a return to the name: Millstone Evans Group previously reported a position in AZN as recently as Q4 2025.

Millstone Evans Group first reported a position in AZN in Q4 2024 and has held it in 6 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Millstone Evans Group held 107 shares of AstraZeneca worth $20.3K as of Q2 2026.
AstraZeneca was a new Millstone Evans Group position in Q2 2026.
AstraZeneca made up 0.01% of Millstone Evans Group's portfolio in Q2 2026, its #497 holding.
Millstone Evans Group first reported a position in AstraZeneca in Q4 2024 and has held it in 6 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.